Kashiv BioSciences

Company

Related News

U.S. insulin glargine and biosimilar market developments point to lower-cost competition

May 14, 2026

U.S. insulin glargine and biosimilar developments in 2026 included CivicaScript's low-cost launch and California's CalRx rollout. The global insulin biosimilars market reached US$2.5 billion in 2025 and is projected to reach US$6.0 billion by 2033.

Dr. Reddy's Gains FDA Acceptance for First Abatacept Biosimilar in U.S.

Feb 21, 2026

Dr. Reddy's Laboratories secures FDA acceptance for DRL-AB, the first abatacept biosimilar application in the U.S., targeting a market worth $3.7 billion annually and positioning the company for first-mover advantage.